Genicular Nerve Block in Rheuamtoid Arthritis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

64 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-04-15

Study Completion Date

2020-07-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

N=64 RA patients either early or established disease diagnosed after ACR/EULAR criteria 2010 with unilateral persistent knee arthritis. They were randomly assigned into two groups; group 1 received genicular nerve block, group 2 intra-articular triamcinolone. Both groups were examined by SOLAR scoring system, Visual analogue scale (VAS) and Lysholm score at 0, 2 and 12 weeks. A semi-quantitative score was used to assess tenderness and swelling at the same intervals.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Genicular Nerve Block in Juvenile Idiopathic Arthritis

NCT04687930

Juvenile Idiopathic Arthritis Persistent Knee Arthritis no Intra-articular Injection in the Last 3 Months +1 more

COMPLETED PHASE4

Efficacy of Hyaluronic Acid Injection in Knee Osteoarthritis

NCT06279507

Knee Osteoarthritis Pain, Joint Stiffness of Knee, Not Elsewhere Classified +1 more

RECRUITING PHASE4

Ecoguided Genicular Nerve Block

NCT06619080

Osteoarthritis, Knee/Rehabilitation

COMPLETED NA

Genicular Nerve Block in Chronic Knee Osteoarthritis

NCT07174167

Gonarthrosis; Primary Genicular Nerve Block Gonarthritis

COMPLETED NA

Study of Safety, Tolerability, Preliminary Efficacy of Intra-articular LNA043 Injections in Patients With Articular Cartilage Lesions and Knee Osteoarthritis.

NCT03275064

Osteoarthritis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain Joint Function Disorder Inflammation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Group received nerve block and another group received steroid

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

The participants does not know the nature of the injected material. Syringe was colored to cover it

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nerve block group

3 point genicular nerve block under ultrasound guidance. half ml of Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer) was injected in each point.

Group Type ACTIVE_COMPARATOR

Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer)

Intervention Type DRUG

3 point genicular nerve block

triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip)

Intervention Type DRUG

intra-articular injection of triamcinilone

intra-articular steroid injection

1 mL of triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip) was injected intraarticular.

Group Type OTHER

Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer)

Intervention Type DRUG

3 point genicular nerve block

triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip)

Intervention Type DRUG

intra-articular injection of triamcinilone

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer)

3 point genicular nerve block

Intervention Type DRUG

triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip)

intra-articular injection of triamcinilone

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* RA patients
* Age \> 18
* unilateral persistent knee arthritis

Exclusion Criteria

* Participants with severe knee osteoarthritis
* peripheral neuropathy
* psoriatic arthritis
* skin infection
* or those who have allergy for Bupivacaine

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No